




PHARMACEUTICAL 2017

RespireRx Pharmaceuticals Inc.
Rank 284 of 292





PHARMACEUTICAL 2017

RespireRx Pharmaceuticals Inc.
Rank 284 of 292

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 688% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 417% points.

The company's Economic Capital Ratio, given in the ranking table, is -627%, being 630% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	196
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,727
Liabilities, Non-Current	0
Other Assets	33
Other Compr. Net Income	0
Other Expenses	774
Other Liabilities	0
Other Net Income	16
Other Revenues	0
Property and Equipment	5.2
Research and Development	3,176
Selling, General and Administrative Expense	5,296

Output Variable	Value in 1000 USD
Assets	234
Liabilities	5,727
Expenses	9,245
Revenues	0
Stockholders Equity	-5,493
Net Income	-9,230
Comprehensive Net Income	-9,230
Economic Capital Ratio	-627%